Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
Pink SheetEli Lilly and Novo Nordisk may be considering big US price reductions for GLP-1 drugs for obesity and diabetes, at least partly in response to President Trump’s recent executive order on Most Fav
ScripFollowing up on last year’s approval of Vyloy (zolbetuximab) and looking to build its pipeline of antibody-drug conjugate (ADC) therapies for cancer, Astellas unveiled a licensing agreement with China
ScripRoivant has promised investors it will spend some of its impressive cash stockpile on buying new assets. But midway into the year, no deals have been signed. CEO Matt Gline, in an interview at the com